Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease
| Condition(s) | Platelet Recovery After Umbilical Cord Blood Transplantation |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease |
| Who can participate | Inclusion Criteria: * Age ≥12 years old, male or female; * Patients diagnosed with bone marrow failure disease including aplastic anemia (AA), Fanconi anemia (FA), paroxysmal nocturnal hemoglobinuria (PNH) and undergoing UCBT; * ECOG score ≤2; * Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent； Exclusion Criteria: * Pregnant or lactating women； * Known allergy to Avatrombopag; * A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation; * A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening; * Chronic active |
| Ages | 12 Years |
| Sex | All |
| Lead sponsor | Anhui Provincial Hospital |
| Locations | Hefei, Anhui, China |
| Start date | 2023-05-04 |
| NCT ID | NCT05823376 |
| Official listing | https://clinicaltrials.gov/study/NCT05823376 |